2026-06-14T03:35:59Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/66902024-09-27T08:10:15Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605col_20.500.12105_19607

00925njm 22002777a 4500 dc Pellinen, Teijo author Blom, Sami author Sanchez, Sara author Valimaki, Katja author Mpindi, John-Patrick author Azegrouz, Hind author Strippoli, Raffaele author Nieto-Arellano, Rocio author Viton, Mariano author Palacios, Irene author Turkki, Riku author Wang, Yinhai author Sanchez-Alvarez, Miguel author Nordling, Stig author Butzow, Anna author Mirtti, Tuomas author Rannikko, Antti author Montoya, Maria author Kallioniemi, Olli author del Pozo, Miguel Angel author 2018 Caveolin-1 (CAV1) is over-expressed in prostate cancer (PCa) and is associated with adverse prognosis, but the molecular mechanisms linking CAV1 expression to disease progression are poorly understood. Extensive gene expression correlation analysis, quantitative multiplex imaging of clinical samples, and analysis of the CAV1-dependent transcriptome, supported that CAV1 re-programmes TGF beta signalling from tumour suppressive to oncogenic (i.e. induction of SLUG, PAI-1 and suppression of CDH1, DSP, CDKN1A). Supporting such a role, CAV1 knockdown led to growth arrest and inhibition of cell invasion in prostate cancer cell lines. Rationalized RNAi screening and high-content microscopy in search for CAV1 upstream regulators revealed integrin beta1 (ITGB1) and integrin associated proteins as CAV1 regulators. Our work suggests TGF beta signalling and beta1 integrins as potential therapeutic targets in PCa over-expressing CAV1, and contributes to better understand the paradoxical dual role of TGF beta in tumour biology. Sci Rep. 2018; 8(1):2338 10.1038/s41598-018-20161-2 2045-2322 Scientific Reports 29402961 http://hdl.handle.net/20.500.12105/6690 ITGB1-dependent upregulation of Caveolin-1 switches TGF beta signalling from tumour-suppressive to oncogenic in prostate cancer